Samsung Invests 156 Billion KRW in US's Grail for Early Cancer Diagnosis via Blood Test

➀ Samsung C&T and Samsung Electronics jointly invested $110 million (156 billion KRW) in Grail, a U.S. biotech company specializing in early cancer detection through blood-based DNA analysis and AI-driven genomic technology;➁ Grail's 'Galleri' test, launched in 2021, identifies over 50 cancer types with a single blood draw and has conducted approximately 400,000 tests globally, including trials with the UK's NHS;➂ Samsung C&T secured exclusive distribution rights in South Korea, while Samsung Electronics plans to integrate Grail's technology into its health platform to enhance personalized healthcare experiences.